As a result, the inhibition of HDAC6 activity represents an exciting therapeutic possibility in high‐grade/stage, invasive or metastatic EC harbouring ARID1A mutations, since metastasis is the main cause of death in patients with cancer. Here, HDAC6 is linked to cancer.